Solanezumab is a monoclonal antibody which binds soluble amyloid preferentially and had shown some promise of promoting better clearance of amyloid-beta from the brain in pre-clinical studies.
Two placebo controlled trials (EXPEDITION 1 and EXPEDITION 2) of 1012 and 1040 patients with mild-moderate Alzheimer’s disease, respectively, have been conducted. These clinical trials have found that Solanezumab did not improve cognition or functional ability.
Full Text Link (Note: This article requires a suitable Athens password, a journal subscription or payment for access).
Doody, RS. Thomas, RG. [and] Farlow, M. [et al] (2014). Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. New England Journal of Medicine, January 23rd 2014, Vol.370(4), pp.311-21. (Click here to view the PubMed abstract).